Skip To Content
Click for DHHS Home Page
Click for the SAMHSA Home Page
Click for the OAS Drug Abuse Statistics Home Page
Click for What's New
Click for Recent Reports and HighlightsClick for Information by Topic Click for OAS Data Systems and more Pubs Click for Data on Specific Drugs of Use Click for Short Reports and Facts Click for Frequently Asked Questions Click for Publications Click to send OAS Comments, Questions and Requests Click for OAS Home Page Click for Substance Abuse and Mental Health Services Administration Home Page Click to Search Our Site

Characteristics of Primary Benzodiazepine Admissions: 2000

The DASIS Report:  Characteristics of Primary Benzodiazepine Admissions:  2000

Highlights:

  • Benzodiazepines are a class of central nervous system depressant drugs commonly prescribed for short-term treatment of anxiety or insomnia.  Proprietary names for drugs in this group include Valium, Xanax, Librium, and Halcion.

  • Of the 23,000 admissions in SAMHSA's Treatment Episode Data Set (TEDS) that involved benzodiazepines, only 19 percent were for primary benzodiazepine use; 81 percent were reported as secondary to the use of alcohol or another drug.

  • Primary benzodiazepine admissions were more than twice as likely as other admissions to have a psychiatric problem in addition to substance abuse (40 vs. 17 percent), which is consistent with the use of benzodiazepines in the treatment of some psychiatric disorders.

  • Compared with other admissions, primary benzodiazepine admissions were more likely to have some college education and less likely to be employed full time.

Reports on treatment

Other Topics

Other Drugs

Help finding other OAS reports

This Short Report,  The DASIS Report:  Characteristics of Primary Benzodiazepine Admissions:  2000, is based on the Drug and Alcohol Services Information System (DASIS), the primary source of national data on substance abuse treatment.  DASIS is conducted by the Office of Applied Studies (OAS) in the Substance Abuse and Mental Health Services Administration (SAMHSA).

This is the page footer.

This page has been accessed 59867 times since 11/25/03.

This page was last updated on November 25, 2007.

SAMHSA, an agency in the Department of Health and Human Services, is the Federal Government's lead agency for improving the quality and availability of substance abuse prevention, addiction treatment, and mental health services in the United States.

Yellow Line

Site Map | Contact Us | Accessibility Privacy PolicyFreedom of Information ActDisclaimer  |  Department of Health and Human ServicesSAMHSAWhite HouseUSA.gov

* Adobe™ PDF and MS Office™ formatted files require software viewer programs to properly read them. Click here to download these FREE programs now

What's New

Highlights Topics Data Drugs Pubs Short Reports Treatment Help Mail OAS